Pravastatin is a statin medication that inhibits HMG-CoA reductase, a key enzyme in cholesterol synthesis. This action primarily lowers LDL ('bad') cholesterol levels, a causal factor in atherosclerosis. By reducing the buildup of plaque in arteries, it significantly decreases the risk of heart attacks and strokes, directly addressing a leading cause of age-related mortality.
Verdict
A cornerstone for reducing cardiovascular risk in appropriate individuals.
HEALTHSPAN IMPACT
High Value
RISK LEVEL
Moderate
EVIDENCE GRADE
A
MONTHLY COST
$5 - $20
Protocol
- Daily oral doses of 10-40 mg are common for primary prevention of cardiovascular disease.
Flags
- Most common side effect is myalgia (muscle pain or weakness).
- Associated with a small but statistically significant increased risk of developing type 2 diabetes.
- Rare but serious side effects include rhabdomyolysis (severe muscle breakdown) and liver damage.
- Pravastatin is hydrophilic, which may result in fewer CNS side effects than lipophilic statins.
- Requires a prescription and medical supervision to monitor lipids and liver function.